Biorithm

Biorithm develops a remote maternal-fetal care platform called femom, designed to deliver home care for pregnant and postnatal patients through connected pregnancy monitoring technology. The femom platform includes a clinical-grade fetal-maternal monitor that records fetal heart rate, maternal heart rate, and uterine contractions using electrophysiological signals, along with patient-reported symptom capture and connected point-of-care devices such as blood pressure monitors and glucometers. The system converts recordings to CTG traces for clinical review and provides a healthcare provider dashboard that enables clinicians to gain insights into mother and baby health while offering expectant mothers better access to healthcare, convenience, and an active role in their pregnancy journey. Founded by doctors and engineers and spun off from Nanyang Technological University, Biorithm's mission is to eliminate preventable poor pregnancy outcomes through mobile technology and data science, addressing the 99% of time pregnant women are not at the clinic. Founded in 2016 and headquartered in Singapore with offices in Cambridge, Massachusetts, the company has raised approximately $3.5M in Series A funding from investors including Adaptive Capital Partners, SEEDS Capital, NTUitive, The Business Collective, MedTech Innovator, Ar Intrepid, and Canopus Advisors. Biorithm differentiates itself through its comprehensive obstetric remote monitoring solution that combines clinical-grade fetal-maternal monitoring with connected POC devices and clinician dashboards for data-driven pregnancy care.